Roadmap for biomarkers of cancer therapy cardiotoxicity
Key result
Novel biomarkers, including myocardial strain, cardiac troponin, and brain natriuretic peptide, are emerging as adjunctive tools to LVEF for the early detection of cancer therapy cardiotoxicity.
Population
Patients receiving cancer therapy at risk of cardiotoxicity
Comparison
Imaging and circulating biomarkers vs Routine assessment of left ventricular ejection…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support adjunctive monitoring in cardio-oncology; leaves open need for prospective validation before practice change.
Structured PICO
P
Population
Patients receiving cancer therapy (chemotherapy, targeted therapy, and radiotherapy) at risk of cardiotoxicity (cardiomyopathy and heart failure)
I
Intervention
Imaging and circulating biomarkers (myocardial strain, cardiac troponin, and brain natriuretic peptide)
C
Comparator
Routine assessment of left ventricular ejection fraction (LVEF)
O
Outcome
Detection and risk stratification of early and late-onset cardiotoxicitysurrogate
Novel imaging and circulating biomarkers offer potential adjunctive prognostic value to routine LVEF assessment for the early detection and management of cancer therapy-induced cardiotoxicity.
Cite This Study
Yu et al. (2015) conducted a review in Cancer therapy cardiotoxicity. Biomarkers (myocardial strain, cardiac troponin, brain natriuretic peptide) was evaluated. Novel biomarkers, including myocardial strain, cardiac troponin, and brain natriuretic peptide, are emerging as adjunctive tools to LVEF for the early detection of cancer therapy cardiotoxicity.